Biodexa Pharmaceuticals Plc (BDRX) Key Metrics
BDRX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · British poundsBDRX returns How much profit the business earns on the capital it uses.
BDRX financial health Debt, liquidity and how easily interest is covered.
BDRX efficiency & capital use Working capital cycle and where the cash goes.
BDRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BDRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BDRX key metrics in British pounds
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Returns & profitability | |||||||
| Return on equity (ROE) | −63.4% | −88.1% | −180.6% | −112.5% | −63.6% | −168.9% | −51.6% |
| Return on invested capital (ROIC) | −126.8% | −221.9% | — | −668.4% | — | — | −60.8% |
| Return on assets (ROA) | −37.9% | −45.2% | −88.1% | −83.0% | −48.0% | −109.0% | −32.6% |
| Return on tangible assets | −49.9% | −62.7% | −93.1% | −138.7% | −42.3% | −226.0% | −54.5% |
| Financial health | |||||||
| Total debt | £60,892 | £727,000 | £464,000 | £624,000 | £766,000 | £260,000 | £6.1M |
| Cash & short-term investments | £8.5M | £1.7M | £6.0M | £2.8M | £10.1M | £7.5M | £10.9M |
| Net debt | −£8.5M | −£942,000 | −£5.5M | −£2.2M | −£9.3M | −£7.3M | −£4.8M |
| Debt / equity | 0.01 | 0.09 | 0.10 | 0.20 | 0.07 | 0.04 | 0.31 |
| Debt / assets | 0.00 | 0.05 | 0.04 | 0.11 | 0.06 | 0.03 | 0.20 |
| Current ratio | 2.03 | 1.75 | 1.26 | 2.47 | 6.39 | 3.10 | 2.42 |
| Quick ratio | 2.03 | 1.75 | 1.39 | 2.47 | 6.39 | 3.56 | 2.42 |
| Interest coverage | -120.8 | -429.0 | -195.5 | -168.5 | -159.0 | -677.6 | -116.7 |
| Working capital | £6.3M | £3.8M | £1.5M | £2.8M | £9.9M | £6.3M | £8.1M |
| Invested capital | £2.9M | £7.4M | −£829,000 | £950,000 | £1.2M | −£568,000 | £14.7M |
| Tangible asset value | £5.7M | £2.7M | £1.7M | £3.2M | £10.5M | £6.7M | £7.2M |
| Net current asset value | £5.7M | £2.4M | £1.2M | £2.3M | £9.3M | £6.2M | £2.4M |
| Capital allocation | |||||||
| Dividends paid | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Capex / revenue | — | — | 69.0% | 8.9% | 55.4% | 60.9% | 47.3% |
| Capex / depreciation | 0.01 | 3.05 | 0.93 | 0.18 | 0.79 | 0.17 | 0.25 |
| Stock-based compensation / revenue | — | — | 7.3% | 17.6% | 15.4% | −117.8% | −5.0% |
| R&D / revenue | — | — | 1,067.5% | 731.2% | 805.2% | 4,707.3% | 1,163.6% |
| SG&A / revenue | — | — | 1,139.6% | 649.8% | 509.7% | 1,445.5% | 569.9% |
| Efficiency | |||||||
| Days sales outstanding | — | — | 494.8 | 94.5 | 40.4 | 1,014.1 | 980.7 |
| Days of inventory on hand | — | — | -31.6 | 0.0 | -54.0 | -41.4 | 0.0 |
| Days payables outstanding | 793.7 | 34.3 | 29.3 | 29.4 | 32.2 | 31.9 | 33.7 |
| Cash conversion cycle (days) | — | — | 433.9 | 65.1 | -45.8 | 940.8 | 947.0 |
| Receivables turnover | 0.00 | 0.00 | 0.74 | 3.86 | 9.03 | 0.36 | 0.37 |
| Payables turnover | 0.46 | 10.65 | 12.46 | 12.41 | 11.32 | 11.43 | 10.82 |
| Inventory turnover | — | — | — | 5,111,000.00 | — | — | 7,843,000.00 |
| Asset turnover | 0.00 | 0.00 | 0.05 | 0.08 | 0.05 | 0.02 | 0.02 |
| Average receivables | £468,304 | £709,500 | £516,500 | £181,000 | £64,000 | £953,000 | £1.8M |
| Average payables | £402,000 | £510,500 | £326,500 | £412,000 | £411,000 | £531,000 | £725,000 |
| Average inventory | — | — | −£352,000 | £1 | −£688,000 | −£688,000 | £1 |
| Intangibles / total assets | 31.1% | 38.2% | 27.9% | 0.1% | 0.0% | 0.0% | 40.1% |
Computed from BDRX's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in British pounds; data from EODHD. Averages use the opening and closing balance of each year.
BDRX valuation and financial ratios
Biodexa Pharmaceuticals Plc earned a return on equity of −63.4% and a return on invested capital of −126.8% in fiscal 2025. It ended the year with £0.1 million of debt and £8.5 million in cash and short-term investments, a net cash position of £8.5 million.
See the BDRX income statement, the BDRX chart for price history, or the BDRX stock overview for the latest quote and news.
BDRX key metrics FAQ
What is Biodexa Pharmaceuticals Plc's return on equity?
Biodexa Pharmaceuticals Plc's return on equity (ROE) was −63.4% in fiscal 2025: net income of -£6.2 million on average shareholders' equity of £9.9 million.
What is Biodexa Pharmaceuticals Plc's ROIC?
Biodexa Pharmaceuticals Plc's return on invested capital was −126.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Biodexa Pharmaceuticals Plc have?
Biodexa Pharmaceuticals Plc had total debt of £0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does Biodexa Pharmaceuticals Plc pay a dividend?
Biodexa Pharmaceuticals Plc did not pay a dividend in fiscal 2025.
What is Biodexa Pharmaceuticals Plc's current ratio?
Biodexa Pharmaceuticals Plc's current ratio was 2.03 at the end of fiscal 2025: current assets were 2.03 times current liabilities.